SCHEMBL115797

SCHEMBL115797

Cc1cnccc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 18/20 0.59
KDM6B O15054 6/20 0.59
KDM4D Q6B0I6 4/20 0.59
KDM4E B2RXH2 3/20 0.59
KDM4A O75164 3/20 0.59
TDP1 Q9NUW8 2/20 0.59
MEN1 O00255 1/20 0.59
ALDH1A1 P00352 1/20 0.59
MAPT P10636 1/20 0.59
THRB P10828 1/20 0.59
KMT2A Q03164 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
SIRT3 Q9NTG7 1/20 0.52
KDM5C P41229 1/20 0.48
SLCO1B1 Q9Y6L6 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30281300 1.00 KDM4C (0.59) KDM4CKDM6BKDM4DKDM4EKDM4A
Ethane SCHEMBL28674866 0.98 KDM4C (0.57) KDM4CKDM6BKDM4DKDM4EKDM4A
Hydrochloric Acid SCHEMBL30369111 0.98 KDM4C (0.57) KDM4CKDM6BKDM4DKDM4EKDM4A
Hydrochloric Acid SCHEMBL11087032 0.98 KDM4C (0.57) KDM4CKDM6BKDM4DKDM4EKDM4A
Hydrochloric Acid SCHEMBL11086902 0.98 KDM4C (0.57) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL8691521 0.91 KDM4C (0.50) KDM4CKDM6BKDM4DKDM4EKDM4A
Trifluoroacetic Acid SCHEMBL30368991 0.89 KDM4C (0.49) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL29571308 0.83 TDP1 (0.68) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL1885868 0.83 TDP1 (0.52) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL258230 0.83 TDP1 (0.68) KDM4CKDM6BKDM4DKDM4EKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1086 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122037226-A Bimetallic-organic framework material for trapping trifluoromethane, preparation method thereof and adsorbent based on bimetallic-organic framework material 西安交通大学 2026-05-15 CN claimed
EP-4687829-A1 COMPOSITION FOR CARING FOR KERATIN MATERIALS L'OREAL (FR) 2026-02-11 EP claimed
US-20250381116-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME OREAL (FR) 2025-12-18 US claimed
US-20250161201-A1 COSMETIC COMPOSITION THE BOOTS COMPANY PLC (GB) 2025-05-22 US claimed
WO-2025091220-A2 COMPOSITION IN THE FORM OF OIL-IN-WATER EMULSION L'OREAL (FR) 2025-05-08 WO claimed
WO-2025091239-A1 COMPOSITION IN THE FORM OF OIL-IN-WATER EMULSION L'OREAL (FR) 2025-05-08 WO claimed
EP-4543408-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME L'OREAL (FR) 2025-04-30 EP claimed
EP-4479146-A1 COSMETIC COMPOSITION The Boots Company PLC (GB) 2024-12-25 EP claimed
WO-2024197798-A1 COMPOSITION FOR CARING FOR KERATIN MATERIALS L'OREAL (FR) 2024-10-03 WO claimed
CN-118420919-A Metal organic framework material with trivalent boron blocked Lewis acid-base pair with fixed structures at two ends, preparation method and application thereof 武汉大学 2024-08-02 CN claimed
EP-1651232-A2 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES Synta Pharmaceuticals Corporation (US) 2006-05-03 EP claimed
US-20050148633-A1 Calcium channel blockers and releasing ions for prodrugs SYNTA PHARMACEUTICALS CORP. 2005-07-07 US claimed
US-20050107436-A1 phenyl and pyridyl derivatives such as 3-Fluoro-N-(2'-trifluoromethyl-biphenyl-4-yl)-isonicotinamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders SYNTA PHARMACEUTICALS CORP. 2005-05-19 US claimed
WO-2005009954-A2 METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS SYNTA PHARMACEUTICALS, CORP. (US) 2005-02-03 WO claimed
WO-2005009539-A2 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS, CORP. (US) 2005-02-03 WO claimed
EP-1367985-A2 ANHYDROUS ANTIPERSPIRANT AND DEODORANT COMPOSITIONS CONTAINING A SOLID, WATER-SOLUBLE, SKIN ACTIVE AGENT THE PROCTER & GAMBLE COMPANY (US) 2003-12-10 EP claimed
EP-0896522-B1 METHODS OF REGULATING SKIN APPEARANCE WITH VITAMIN B 3 COMPOUND PROCTER & GAMBLE (US) 2003-10-22 EP claimed
WO-2002069916-A2 ANHYDROUS ANTIPERSPIRANT AND DEODORANT COMPOSITIONS CONTAINING A SOLID, WATER-SOLUBLE, SKIN ACTIVE AGENT THE PROCTER & GAMBLE COMPANY (US) 2002-09-12 WO claimed
US-6383476-B1 Anhydrous antiperspirant and deodorant compositions containing a solid, water-soluble, skin active agent THE PROCTER & GAMBLE COMPANY 2002-05-07 US claimed
EP-0095341-B1 PENICILLANIC ACID DIOXIDE PRODRUG PFIZER INC. (US) 1986-02-26 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148633-A1 Calcium channel blockers and releasing ions for prodrugs ORAI1, CACNA1C, CACNA1F KDM4C 1567/4885KDM6B 1768/4885KDM4D 2708/4885
US-20250161201-A1 COSMETIC COMPOSITION CYP19A1, SHBG, HSD17B11 KDM4C 2767/4885KDM6B 2418/4885KDM4D 2675/4885
US-20250381116-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME TBCB, CCNB3, CYP24A1 KDM4C 563/4885KDM6B 1015/4885KDM4D 624/4885
US-20050107436-A1 phenyl and pyridyl derivatives such as 3-Fluoro-N-(2'-trifluoromethyl-biphenyl-4-yl)-isonicotinamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders TPMT, PTPN3, FKBP3 KDM4C 1774/4885KDM6B 1012/4885KDM4D 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.